Form 8-K - Current report:
SEC Accession No. 0001650664-25-000123
Filing Date
2025-08-12
Accepted
2025-08-12 16:03:42
Documents
15
Period of Report
2025-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K edit-20250812.htm   iXBRL 8-K 27202
2 EX-99.1 editasmedicinepressrelease.htm EX-99.1 64772
7 image_0a.jpg GRAPHIC 61309
  Complete submission text file 0001650664-25-000123.txt   312966

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT edit-20250812.xsd EX-101.SCH 2129
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT edit-20250812_def.xml EX-101.DEF 2931
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT edit-20250812_lab.xml EX-101.LAB 23733
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT edit-20250812_pre.xml EX-101.PRE 14223
17 EXTRACTED XBRL INSTANCE DOCUMENT edit-20250812_htm.xml XML 2908
Mailing Address 11 HURLEY ST. CAMBRIDGE MA 02141
Business Address 11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Editas Medicine, Inc. (Filer) CIK: 0001650664 (see all company filings)

EIN.: 464097528 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)